Literature DB >> 24326276

Comparative molecular field analysis of fenoterol derivatives interacting with an agonist-stabilized form of the β₂-adrenergic receptor.

Anita Plazinska1, Karolina Pajak1, Ewelina Rutkowska1, Lucita Jimenez2, Joseph Kozocas2, Gary Koolpe2, Mary Tanga2, Lawrence Toll3, Irving W Wainer4, Krzysztof Jozwiak5.   

Abstract

The β₂-adrenergic receptor (β₂-AR) agonist [(3)H]-(R,R')-methoxyfenoterol was employed as the marker ligand in displacement studies measuring the binding affinities (Ki values) of the stereoisomers of a series of 4'-methoxyfenoterol analogs in which the length of the alkyl substituent at α' position was varied from 0 to 3 carbon atoms. The binding affinities of the compounds were additionally determined using the inverse agonist [(3)H]-CGP-12177 as the marker ligand and the ability of the compounds to stimulate cAMP accumulation, measured as EC₅₀ values, were determined in HEK293 cells expressing the β₂-AR. The data indicate that the highest binding affinities and functional activities were produced by methyl and ethyl substituents at the α' position. The results also indicate that the Ki values obtained using [(3)H]-(R,R')-methoxyfenoterol as the marker ligand modeled the EC₅₀ values obtained from cAMP stimulation better than the data obtained using [(3)H]-CGP-12177 as the marker ligand. The data from this study was combined with data from previous studies and processed using the Comparative Molecular Field Analysis approach to produce a CoMFA model reflecting the binding to the β₂-AR conformation probed by [(3)H]-(R,R')-4'-methoxyfenoterol. The CoMFA model of the agonist-stabilized β₂-AR suggests that the binding of the fenoterol analogs to an agonist-stabilized conformation of the β₂-AR is governed to a greater extend by steric effects than binding to the [(3)H]-CGP-12177-stabilized conformation(s) in which electrostatic interactions play a more predominate role.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Agonist-stabilized conformations; Antagonist-stabilized conformations; [(3)H]-(R,R′)-4′-methoxyfenoterol; β(2)-Adrenoceptor conformations; β(2)-Adrenoceptor selective agonist

Mesh:

Substances:

Year:  2013        PMID: 24326276      PMCID: PMC3908673          DOI: 10.1016/j.bmc.2013.11.030

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  {Beta}2-adrenergic receptor agonists inhibit the proliferation of 1321N1 astrocytoma cells.

Authors:  L Toll; L Jimenez; N Waleh; K Jozwiak; A Y-H Woo; R-P Xiao; M Bernier; I W Wainer
Journal:  J Pharmacol Exp Ther       Date:  2010-11-11       Impact factor: 4.030

2.  MolDock: a new technique for high-accuracy molecular docking.

Authors:  René Thomsen; Mikael H Christensen
Journal:  J Med Chem       Date:  2006-06-01       Impact factor: 7.446

3.  Thermodynamics and docking of agonists to the β(2)-adrenoceptor determined using [(3)H](R,R')-4-methoxyfenoterol as the marker ligand.

Authors:  Lawrence Toll; Karolina Pajak; Anita Plazinska; Krzysztof Jozwiak; Lucita Jimenez; Joseph A Kozocas; Mary J Tanga; James E Bupp; Irving W Wainer
Journal:  Mol Pharmacol       Date:  2012-03-20       Impact factor: 4.436

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  Stereochemistry of an agonist determines coupling preference of beta2-adrenoceptor to different G proteins in cardiomyocytes.

Authors:  Anthony Yiu-Ho Woo; Tian-Bing Wang; Xiaokun Zeng; Weizhong Zhu; Darrell R Abernethy; Irving W Wainer; Rui-Ping Xiao
Journal:  Mol Pharmacol       Date:  2008-10-07       Impact factor: 4.436

6.  The role of ligands on the equilibria between functional states of a G protein-coupled receptor.

Authors:  Tae Hun Kim; Ka Young Chung; Aashish Manglik; Alexandar L Hansen; Ron O Dror; Thomas J Mildorf; David E Shaw; Brian K Kobilka; R Scott Prosser
Journal:  J Am Chem Soc       Date:  2013-06-14       Impact factor: 15.419

7.  Comparative molecular field analysis of the binding of the stereoisomers of fenoterol and fenoterol derivatives to the beta2 adrenergic receptor.

Authors:  Krzysztof Jozwiak; Chakir Khalid; Mary J Tanga; Ilona Berzetei-Gurske; Lucita Jimenez; Joseph A Kozocas; Anthony Woo; Weizhong Zhu; Rui-Ping Xiao; Darrell R Abernethy; Irving W Wainer
Journal:  J Med Chem       Date:  2007-05-17       Impact factor: 7.446

8.  Comparative molecular field analysis of fenoterol derivatives: A platform towards highly selective and effective beta(2)-adrenergic receptor agonists.

Authors:  Krzysztof Jozwiak; Anthony Yiu-Ho Woo; Mary J Tanga; Lawrence Toll; Lucita Jimenez; Joseph A Kozocas; Anita Plazinska; Rui-Ping Xiao; Irving W Wainer
Journal:  Bioorg Med Chem       Date:  2009-12-06       Impact factor: 3.641

9.  Pharmacokinetics and metabolism of (R,R)-methoxyfenoterol in rat.

Authors:  D Siluk; D E Mager; H S Kim; Y Wang; A M Furimsky; A Ta; L V Iyer; C E Green; I W Wainer
Journal:  Xenobiotica       Date:  2010-03       Impact factor: 1.908

10.  Crystal structure of the β2 adrenergic receptor-Gs protein complex.

Authors:  Søren G F Rasmussen; Brian T DeVree; Yaozhong Zou; Andrew C Kruse; Ka Young Chung; Tong Sun Kobilka; Foon Sun Thian; Pil Seok Chae; Els Pardon; Diane Calinski; Jesper M Mathiesen; Syed T A Shah; Joseph A Lyons; Martin Caffrey; Samuel H Gellman; Jan Steyaert; Georgios Skiniotis; William I Weis; Roger K Sunahara; Brian K Kobilka
Journal:  Nature       Date:  2011-07-19       Impact factor: 49.962

  10 in total
  7 in total

1.  Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding.

Authors:  Michael T Reinartz; Solveig Kälble; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-31       Impact factor: 3.000

2.  Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor.

Authors:  Michael T Reinartz; Solveig Kälble; Timo Littmann; Takeaki Ozawa; Stefan Dove; Volkhard Kaever; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-10-24       Impact factor: 3.000

3.  Activation of β2-adrenergic receptor by (R,R')-4'-methoxy-1-naphthylfenoterol inhibits proliferation and motility of melanoma cells.

Authors:  Artur Wnorowski; Mariola Sadowska; Rajib K Paul; Nagendra S Singh; Anna Boguszewska-Czubara; Lucita Jimenez; Kotb Abdelmohsen; Lawrence Toll; Krzysztof Jozwiak; Michel Bernier; Irving W Wainer
Journal:  Cell Signal       Date:  2015-02-20       Impact factor: 4.315

4.  Recruitment of β-arrestin 1 and 2 to the β2-adrenoceptor: analysis of 65 ligands.

Authors:  Timo Littmann; Martin Göttle; Michael T Reinartz; Solveig Kälble; Irving W Wainer; Takeaki Ozawa; Roland Seifert
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

5.  Toward G protein-coupled receptor structure-based drug design using X-ray lasers.

Authors:  Andrii Ishchenko; Benjamin Stauch; Gye Won Han; Alexander Batyuk; Anna Shiriaeva; Chufeng Li; Nadia Zatsepin; Uwe Weierstall; Wei Liu; Eriko Nango; Takanori Nakane; Rie Tanaka; Kensuke Tono; Yasumasa Joti; So Iwata; Isabel Moraes; Cornelius Gati; Vadim Cherezov
Journal:  IUCrJ       Date:  2019-10-24       Impact factor: 4.769

Review 6.  Structural Insights into Ligand-Receptor Interactions Involved in Biased Agonism of G-Protein Coupled Receptors.

Authors:  Krzysztof Jóźwiak; Anita Płazińska
Journal:  Molecules       Date:  2021-02-06       Impact factor: 4.411

7.  Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives.

Authors:  Anthony Yiu-Ho Woo; Xin-Yue Ge; Li Pan; Gang Xing; Yong-Mei Mo; Rui-Juan Xing; Xiao-Ran Li; Yu-Yang Zhang; Irving W Wainer; Mao-Sheng Cheng; Rui-Ping Xiao
Journal:  Acta Pharmacol Sin       Date:  2019-01-14       Impact factor: 6.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.